Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Down 13.3% in November

Daré Bioscience, Inc. (NASDAQ:DARE) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 25,500 shares, a decline of 13.3% from the October 31st total of 29,400 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily volume of 41,600 shares, the days-to-cover ratio is currently 0.6 days.

Analyst Ratings Changes

A number of research analysts recently commented on DARE shares. Maxim Group restated a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Daré Bioscience in a report on Friday, November 15th.

Daré Bioscience Price Performance

Shares of Daré Bioscience stock traded up $0.12 during midday trading on Friday, reaching $3.42. The company had a trading volume of 26,983 shares, compared to its average volume of 52,958. The stock has a fifty day moving average price of $3.55 and a 200 day moving average price of $3.89. Daré Bioscience has a fifty-two week low of $3.05 and a fifty-two week high of $7.56.

Institutional Investors Weigh In On Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC boosted its stake in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 as of its most recent SEC filing. 6.70% of the stock is currently owned by institutional investors.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.